| NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NCT05197322) | University College, London | 2022-07-20 |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (NCT05080673) | NRG Oncology | 2022-02-09 |
| Intracorporeal Versus Extracorporeal Anastomosis In Laparoscopic Right Colon Resection (NCT05077358) | Yonsei University | 2021-04-05 |
| MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab (NCT04554836) | TheraOp | 2020-12-29 |
| Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation (NCT04668872) | Memorial Sloan Kettering Cancer Center | 2020-12-07 |
| Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (NCT03871959) | Centre Leon Berard | 2019-09-15 |
| Prospective Study of Oncologic Outcomes After Laparoscopic Modified Complete Mesocolic Excision for Non-metastatic Right Colon Cancer [PIONEER Study] (NCT03992599) | Yonsei University | 2019-08-01 |
| Human Intestinal Microbiome and Surgical Outcomes in Patients Undergoing Colorectal Cancer Surgery (NCT04005118) | Assistance Publique - Hôpitaux de Paris | 2019-05-28 |
| Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX (NCT02425683) | US Oncology Research | 2015-03-26 |
| Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer (NCT02046538) | Weill Medical College of Cornell University | 2014-02-01 |
| Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer (NCT01606124) | Mayo Clinic | 2012-06-01 |
| Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer (NCT01455831) | Ottawa Hospital Research Institute | 2011-09-01 |
| Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (NCT01294826) | Swedish Medical Center | 2011-02-01 |
| Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer (NCT01270438) | National Cancer Institute (NCI) | 2010-12-01 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment (NCT00942266) | Roswell Park Cancer Institute | 2009-07-01 |
| Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer (NCT00707889) | AbbVie (prior sponsor, Abbott) | 2008-10-01 |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer (NCT00551421) | National Cancer Institute (NCI) | 2007-10-01 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (NCT00397384) | National Cancer Institute (NCI) | 2007-01-01 |
| Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery (NCT00433576) | National Cancer Institute (NCI) | 2006-12-01 |
| AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer (NCT00397878) | National Cancer Institute (NCI) | 2006-11-01 |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer (NCT00070122) | National Cancer Institute (NCI) | 2004-04-01 |
| Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer (NCT00079274) | National Cancer Institute (NCI) | 2004-02-01 |
| Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer (NCT00052585) | National Cancer Institute (NCI) | 2002-10-01 |
| Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver (NCT00026234) | National Cancer Institute (NCI) | 2002-02-01 |
| Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer (NCT00032110) | National Cancer Institute (NCI) | 2002-01-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer (NCT00023933) | National Cancer Institute (NCI) | 2001-10-01 |
| Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated (NCT00025337) | National Cancer Institute (NCI) | 2001-09-01 |
| SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer (NCT00005818) | National Cancer Institute (NCI) | 2000-03-01 |
| Combination Chemotherapy in Treating Patients With Stage III Colon Cancer (NCT00003835) | National Cancer Institute (NCI) | 1999-05-01 |
| Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer (NCT00003873) | National Cancer Institute (NCI) | 1999-04-01 |
| Antineoplaston Therapy in Treating Patients With Colon Cancer (NCT00003486) | Burzynski Research Institute | |